Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin (R) added to standard therapy in patients with lung cancer
Κύριοι συγγραφείς: | Macbeth, F, Griffiths, G, Noble, S, Burns, S, Maughan, T |
---|---|
Μορφή: | Journal article |
Έκδοση: |
2009
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer
ανά: Griffiths, G, κ.ά.
Έκδοση: (2009) -
FRAGMATIC: A randomised phase III clinical trial investigating the effect of <b>fragm</b>in<sup>® </sup><b>a</b>dded to standard <b>t</b>herapy <b>i</b>n patients with lung <b>c</b>ancer
ανά: Macbeth Fergus R, κ.ά.
Έκδοση: (2009-10-01) -
Releasing interim results from a randomised clinical trial: an example from the QUARTZ trial
ανά: Nankivell Matthew, κ.ά.
Έκδοση: (2011-12-01) -
Gelsolin-Like Domain 3 Plays Vital Roles in Regulating the Activities of the Lily Villin/Gelsolin/Fragmin Superfamily.
ανά: Dong Qian, κ.ά.
Έκδοση: (2015-01-01) -
Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial
ανά: Anders Kjellberg, κ.ά.
Έκδοση: (2023-01-01)